Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.

Defensive stocks are stealing the spotlight again following Fed Chair Jerome Powell's recent comments. In his address at the Economic Club of Washington D.C.

Bristol-Myers Squibb Company faces challenges with patent expirations and debt from acquisitions, but has strong long-term shareholder return potential. Q1 2024 results show revenue growth and promising regulatory approvals, supporting long-term portfolio growth. The KarXT acquisition and guidance demonstrate commitment to diversification, managing business, and driving future shareholder returns.

The broad market may have recently made new highs, but scores of individual stocks have also hit new 52-week lows. There are a few that could be considered some of the best value stocks to buy.

24/7 Insights The stock market entered the third quarter overbought and may be ready for a big correction Stifel's Barry Bannister has called huge market moves in the past Grab this incredible free report now Access 2 legendary, high-yield dividend stocks Wall Street loves If there is one voice on Wall Street that we always listen to at 24/7 Wall St, it's Stifel's Barry Bannister, and with good reason.

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Medicines Agency Validation of Application for Opdivo plus Yervoy for First-Line Treatment of Unresectable or Advanced HCC.

The latest trading day saw Bristol Myers Squibb (BMY) settling at $42.39, representing a -1.76% change from its previous close.

Bristol-Myers Squibb reported first quarter results and had to lower its guidance for fiscal 2024 due to the IPRD acquisition for $12.9 billion. The company will also lose patent protection for Revlimid, Opdivo and Eliquis, which is a huge part of their revenue. But the company is trying to shift its portfolio from its legacy products to its growth products.

Bristol Myers Squibb is down big this year, but with a growth strategy in place, it can make for an appealing contrarian investment. AT&T's business is growing, and its strong free cash flow could pave the way for a rising dividend.

Bristol-Myers Squibb continues to underperform the wider market with bullish support yet to materialize, despite the double beat FQ1'24 earnings call, cost-saving strategies, and numerous regulatory wins. With BMY stock seemingly behaving like a falling knife, our previous Buy rating has not panned out well indeed. However, we are reiterating our optimism surrounding BMY's dividend investment thesis and growing in-house/acquired pipelines, with the second half of the decade likely to be promising.

According to NextEarningsDate.com, the Bristol-Myers Squibb next earnings date is projected to be 7/26 before market open, with earnings estimates of $1.53/share on $10.56 Billion of revenue.